Recent Updates
Recently added Catalysts

KW-3902IV

Phase 2

Heart Failure, Congestive | Small molecule | Cardiovascular |Merck & Company, Inc.|Last Updated: Jan 29, 2008

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindUNCONTROLLEDBiomarker
Total Trials2
Total Enrollment82

FDA Designations

No designations recorded

Clinical trial landscape

KW-3902IV · 2 trials · 2 indications

Phase 2 2
NCT00159614Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal ImpairmentHeart Failure, Congestive
COMPLETED30 Analytics
NCT00159627Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).Heart Failure, Congestive
COMPLETED52 Analytics
PHASE2COMPLETED
Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment
Heart Failure, Congestive
NCT0015961430
Unlock trial analytics
PHASE2COMPLETED
Dose Escalation Study of KW-3902 on Diuresis in Subjects With Congestive Heart Failure (CHF).
Heart Failure, Congestive
NCT0015962752
Unlock trial analytics

Study Endpoints

Primary Endpoints

Comparison of KW-3902IV alone or with loop diuretic on renal function.
Change in urine volume from baseline
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingDOUBLE
ModelCROSSOVER
PurposeTREATMENT

Interventions

NameTypeDescription
KW-3902IVDRUG -
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites6

Inclusion Criteria: * Stable congestive heart failure * Impaired renal function * Taking oral loop diuretic Exclusion Criteria: * Acutely decompensated (unstable) and end stage heart failure * Diuretics other than loop diuretics * Pregnant or nursing * Inability to follow instructions * Participa...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about KW-3902IV

What is KW-3902IV used for?

KW-3902IV is an investigational small molecule being developed for congestive heart failure. It is being studied in combination with intravenous furosemide to evaluate its effect on renal function in subjects with congestive heart failure and renal impairment, as well as for its diuretic effects in congestive heart failure.

Who makes KW-3902IV?

KW-3902IV is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in patients with congestive heart failure.

What phase is KW-3902IV in?

KW-3902IV is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. Two Phase 2 trials have been completed, with a total enrollment of 82 participants.

What clinical trials is KW-3902IV in?

KW-3902IV has been studied in two completed Phase 2 clinical trials. NCT00159614 evaluated the drug in combination with IV furosemide in subjects with congestive heart failure and renal impairment, enrolling 30 participants. NCT00159627 was a dose escalation study of KW-3902 on diuresis in subjects with congestive heart failure, enrolling 52 participants.

Is KW-3902IV the same as KW-3902?

KW-3902IV is the intravenous formulation of the drug KW-3902. The 'IV' designation indicates that it is administered intravenously, as opposed to other formulations that may exist. In clinical trials, KW-3902IV is being studied for its effects on renal function and diuresis in congestive heart failure.